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Abstract  16 
Dysfunction at glutamatergic synapses has been proposed as a mechanism in the 17 
development of neuropathic pain. Here we sought to determine whether peripheral nerve 18 
injury-induced neuropathic pain results in functional changes to primary afferent synapses. 19 
Signs of neuropathic pain as well as an induction of glial fibrillary acidic protein in 20 
immunostained spinal cord sections 4 days after partial ligation of the sciatic nerve 21 
indicated the induction of neuropathic pain. We found that following nerve injury, no 22 
discernable change to kinetics of AMPA or NMDA receptor (NMDAR)-mediated evoked 23 
excitatory post synaptic currents (eEPSCs) could be observed in dorsal horn (lamina I/II) 24 
neurons compared to those of naive mice. However, we did find that nerve injury was 25 
accompanied by slowed decay of the early phase of eEPSCs in the presence of glutamate 26 
transporter inhibition by the competitive non-transportable inhibitor DL-threo-β-27 
Benzyloxyaspartic acid (TBOA). Concomitantly, expression patterns for the two major 28 
glutamate transporters in spinal cord, EAAT1 and EAAT2, were found to be reduced at this 29 
time (4 days post-injury). We then sought to directly determine whether nerve injury results 30 
in glutamate spillover to NMDARs at dorsal horn synapses. By employing the use-dependent 31 
NMDAR blocker (±)MK-801 to block subsynaptic receptors, we found that although TBOA-32 
induced spillover to extra-synaptic receptors trended to increased activation of these 33 
receptors after nerve injury, this was not significant compared to naive mice. Together, 34 
these results suggest the development of neuropathic pain involves subtle changes to 35 
glutamate transporter expression and function that could contribute to neuropathic pain 36 
during excessive synaptic activity. 37 
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Introduction 40 
The synaptic mechanisms associated with development of chronic neuropathic pain remain 41 
poorly understood (Graham et al. 2007).  An interplay of both an increase in primary 42 
afferent activity or glutamate release, as well as an impairment of glutamate re-uptake at 43 
primary afferent synapses in the dorsal horn have been proposed as possible mechanisms  44 
for the development of neuropathic pain (Tsuda et al. 2005; Sandkuhler 2007; Scholz and 45 
Woolf 2007). 46 
One of the key components of normal sensory neurotransmission is the tight coupling of 47 
excitatory neurotransmitter release with rapid reuptake. Recovery of synaptic glutamate is 48 
mediated by a family of specific high-affinity membrane transporters (Danbolt 2001), the 49 
excitatory amino acid transporters (EAATs). Astrocytes express two such transporters, 50 
EAAT1 (GLAST, Slc1a3) and EAAT2 (GLT-1, Slc1a2), which are together responsible for the 51 
majority of synaptic glutamate re-uptake (Rothstein et al. 1994; Chaudhry et al. 1995; 52 
Rothstein et al. 1996). A third, neuronal isoform, known as EAAT3 (EAAC1, Slc1a1) is also 53 
found in the spinal cord, on primary afferents  interneurons and motor neurons of the 54 
ventral horn but plays only a limited role in synaptic glutamate re-uptake (Rothstein et al. 55 
1994; Peghini et al. 1997; Stoffel et al. 2004; Sun et al. 2011). Intrathecal administration of 56 
EAAT inhibitors produces pain behaviours suggesting that dysfunction of these transporters 57 
may contribute to signs of neuropathic pain (Liaw et al. 2005; Weng et al. 2006). Findings of 58 
pathological changes to astroglia during development of neuropathic pain have raised the 59 
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possibility that EAAT function may be impaired in the vicinity of primary afferent synapses.  60 
Recent reports have indicated that spinal EAAT expression can both increase and decrease 61 
in the first 7 days following peripheral nerve injury in rodent neuropathic pain models (Sung 62 
et al. 2003; Wang et al. 2006; Sung et al. 2007; Tawfik et al. 2008; Xin et al. 2009) with 63 
substantial losses at day 7 and beyond. It has also been shown that these expression 64 
changes coincide with the development of neuropathic pain. However, exactly how these 65 
expression changes contribute to altered glutamatergic synaptic transmission has not yet 66 
been fully elucidated. 67 
The aims of this study were therefore to determine if peripheral nerve injury influences the 68 
expression and uptake capacity of spinal glutamate transporters at functioning 69 
glutamatergic synapses in spinal cord of nerve injured mice during development of 70 
neuropathic pain. Although behavioural signs and markers of neuropathic pain such as 71 
astrocyte activation were observed after nerve injury, we found only a modest reduction in 72 
glutamate transporter expression after nerve injury and evidence for limited changes to 73 
glutamatergic transmission at primary afferent synapses that would be indicative of 74 
impaired glutamate uptake. 75 
 76 
Materials and Methods 77 
Experimental animals 78 
Animals used in the experiments outlined below were approved for use by The University of 79 
Sydney and University of Technology Sydney Animal Ethics Committees. Experiments were 80 
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performed under the guidelines of the Australian code of practice for the care and use of 81 
animals for scientific purposes (National Health and Medical Research Council, Australia, 7th 82 
Edition). In all experiments unless otherwise stated, 6 – 8 week old inbred C57bl/6 male 83 
mice were used (91 in total). Animals were kept in 12hr light/dark cycles with food 84 
(standard rodent chow) and water provided ad libitum. 85 
 86 
Induction and behavioural assessment of nerve injury 87 
Partial sciatic nerve ligation (PNL) was performed as described previously (Seltzer et al. 88 
1990). Briefly, under isoflurane (Aerrane, Baxter) anaesthesia (2.5% in oxygen), the biceps 89 
femoris muscle was blunt dissected to reveal the sciatic nerve proximal to its trifurcation. 90 
Connective tissue surrounding the nerve was carefully removed to improve access. A spinal 91 
hook was then used to lift the nerve without compression or stretching so that a single 6-0 92 
silk suture could be threaded through approximately one-half of the nerve. This single 93 
suture was tied tightly before returning the nerve to its original position. The musculature 94 
was then sewn together with a single suture and the skin was brought together and closed 95 
with cyanoacrylate glue (VetbondTM, 3MTM). 96 
The impact of nerve injury on hind paw weight bearing was assessed with a Linton 97 
Incapacitance Tester (Linton Instrumentation, UK) prior to and 1, 4 and 7 days following 98 
nerve injury (Strickland et al. 2008). Measurements were taken by averaging the 99 
instantaneous force (measured as weight, in grams) applied to each hind-paw at pre-surgery 100 
(baseline) and each day post-surgery. Each datum is the average of 4 measurements taken 101 
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at 10 second intervals. An incapacitance ratio was therefore derived as the force applied by 102 
the injured hind paw / uninjured paw. Animals that failed to show a 25% or greater 103 
reduction in their incapacitance ratio (7 of the 91 mice) were not used for biochemical or 104 
electrophysiological experiments and were euthanized. 105 
 Immediately following incapacitance measurements, each animal was placed into a 106 
plexiglass observation chamber (40cm x 20cm x 20cm) and was monitored for 5 min for 107 
signs of spontaneous pain by scoring the number of events of hind-paw lifting, hind-paw 108 
flicking or shaking, and hind paw tending. A composite score for each animal was calculated 109 
by summing each score. As the mice were able to move freely about the enclosure, no 110 
scoring bias was applied to the affected paw. 111 
 112 
Immunofluorescent detection of spinal glutamate transporters 113 
Following sodium pentobarbital administration, mice were transcardially perfused with 10 114 
ml of a heparin containing (3000 IU /L) flush solution (in mM; 154 NaCl, 58.8 NaNO3) before 115 
perfusion with 100 ml of the fixation solution; 4% formaldehyde prepared in PBS (in mM; 116 
25.3 NaH2PO4.H2O, 108 Na2HPO4, 154 NaCl). Spinal cords were removed following fixation 117 
and post-fixed for 1 hour, before transferring to 30% sucrose/PBS to cryoprotect the cords. 118 
All steps used PBS as a buffer. Once sucrose had penetrated the cords (as determined by 119 
cords sinking) they were snap-frozen in tissue support matrix (Tissue-Tek® O.C.T. compound, 120 
Proscitech, Thuringowa, QLD, Australia) and stored at -80 oC until processed. Thirty 121 
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micrometer sections were then cut into PBS using a Leica cryostat (CM1850 UV) and stored 122 
at 4 oC. Only sections from the lumbar enlargement (L3 – L5) were used for staining. 123 
For immunofluorescent staining, 6 sections from each of 4 mice per time point (or 4 naive 124 
mice, 12 mice in total) were permeabilised in 0.3% Triton-X100/PBS (wash buffer) for 10 125 
minutes before blocking with 10% normal horse serum (NHS; EAAT1-2) or goat serum (for 126 
GFAP) for 30 minutes. Sections were then transferred into the appropriate primary antibody 127 
diluted in wash buffer (EAAT1 1:4,000 Millipore; EAAT2 1:400 Millipore; EAAT3 1:1000 128 
Millipore; GFAP 1:1,000 Abcam) and incubated overnight at room temperature with gentle 129 
agitation. Excess primary antibody was removed with three 10 minutes washes of wash 130 
buffer before a 2 hour incubation in secondary antibody (EAAT1/2; anti-guinea pig A488, 131 
Jackson ImmunoResearch, GFAP; anti-rabbit A488, InvitrogenTM, EAAT3; anti-mouse Cy3, 132 
Jackson ImmunoResearch). Finally, sections were washed again with three 10 minutes 133 
washes with wash buffer before mounting onto glass slides with fluoromount-G (Southern 134 
Biotech, Alabama, USA). Digital images of individual sections were taken at 10X optical 135 
magnification on an epifluorescent microscope. Densitometry was performed using ImageJ 136 
software (National Institutes of Health, Bethesda USA). For high magnification of GFAP-137 
stained sections, 4 10X confocal images comprising 30 1µm z-sections were stitched 138 
together using Photoshop® (Adobe, San Jose CA) to create one single image. Inlays are 139 
comprised of 9, 60X confocal images comprising 30 1µm z-sections stitched together. 140 
 141 
In vitro electrophysiology 142 
8 
 
Spinal cord slices (340 µm) from the lumbar enlargement L3-L5 (Rigaud et al. 2008) were 143 
prepared from 24 nerve injured and 36 naive isoflurane anaesthetised mice on a Leica 144 
VT1200S vibrating blade microtome (Leica Microsystems, North Ryde, Australia) in ice-cold 145 
modified artificial cerebrospinal fluid (ACSF, in mM); choline chloride (120), glucose (11), 146 
NaHCO3 (25), KCl (2.5), NaH2PO4 (1.4), CaCl2 (0.5), MgCl2 (7), atropine (0.001). Slices were 147 
allowed to recover for 1 hour at room temperature in ACSF (in mM); NaCl (125), KCl (2.5), 148 
NaH2PO4 (1.25), NaHCO3 (25), glucose (11), MgCl2 (1.2), CaCl2 (2.5) before being transferred 149 
to a recording chamber where Dodt-contrast optics was used to identify lamina I/II 150 
superficial dorsal horn neurons for patch-clamp electrophysiology. The internal solution of 151 
the recording pipette contained (in mM); CsCl (140), EGTA (10), HEPES (5), CaCl2 (2), MgATP 152 
(2), NaGTP (0.3), QX314 chloride (5) and had an osmolality of 290 mOsm. Drugs were 153 
superfused onto slices at a rate of 2 ml per minute in normal ACSF at a nominal 33oC. 154 
Whole-cell voltage clamp was performed using a Multiclamp 700B amplifier (Molecular 155 
Devices, Sunnyvale CA) interfaced to an intel processor-based iMac computer (Apple, 156 
Cupertino CA; Mac OS X 10.5) via an ITC-18 digitiser (Heka Elektronik, Ludwigshafen 157 
Germany). Electrically-evoked EPSCs (eEPSCs) were elicited by stimulating dorsal roots 158 
attached to the slice at 0.03Hz with bipolar tungsten electrodes so that an appropriately 159 
sized current was produced in recorded neurons, in the range of 100 – 800 pA. eEPSCs were 160 
sampled at 10 kHz and filtered at 4 kHz using Axograph X (Axograph Scientific, Australia). 161 
AMPA receptor mediated currents were obtained by clamping the membrane potential at -162 
60 mV in the presence of picrotoxin (100 µM), strychnine (5 µM) and DL-AP5 (100 µM). 163 
NMDA receptor mediated currents were obtained by clamping the membrane potential at 164 
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+40 mV in the presence of picrotoxin (100 µM), strychnine (5 µM) and CNQX (10 µM). 165 
Miniature EPSCs were filtered (4 kHz low-pass filter) and sampled at 10 kHz for on-line and 166 
later off-line analysis, and were recorded in the presence of picrotoxin (100 μM), strychnine 167 
(5 μM) and tetrodotoxin (1 μM), to block GABAA, glycine and sodium channels, respectively. 168 
Miniature EPSCs above a preset threshold (4 standard deviations above baseline noise) were 169 
automatically detected by a sliding template algorithm, and then manually checked off-line. 170 
Miniature EPSCs were then counted in 4 s epochs every 2 s to construct rate-time plots. 171 
Data presented represent the average of at least 800 captured events over a minimum 5 172 
minute interval for each condition (drug or vehicle) for each cell recorded (N = 4). Series 173 
resistance (< 20 MΩ) was compensated by 70-80% in all patch-clamp experiments. 174 
Recordings were stopped if series resistance deviated by more than 20% of baseline. 175 
 176 
Data analysis and statistics  177 
Densitometry of immunohistochemistry was performed using imageJ (National Institutes of 178 
Health, Bethseda, USA). Behavioural testing was recorded by the observer in a notebook 179 
before being manually entered into Prism (Version 5 for Windows, GraphPad Software Inc. 180 
California, USA) for statistical analysis and generation of graphs. Illustrations were prepared 181 
using Photoshop® CS4 and Illustrator® CS4 for Windows. Kinetics of AMPAR and NMDAR 182 
evoked EPSCs were determined offline using the ‘fit exponential’ tool in Axograph on the 183 
assembled average of 10 consecutive eEPSCs for each condition. The kinetics of 184 
unperturbed (in the absence of uptake inhibitors) eEPSC decay were best described by a 185 
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single exponential. As with previous reports, the addition of a second exponential did not 186 
improve the quality of the fit (Grosskreutz et al. 2003). Rise and decay kinetics for each 187 
recording were only included for analysis if the assembled average trace was smooth 188 
enough to confidently measure these parameters. The area under the curve was also 189 
determined for each trace using Axograph. Statistical differences were determined using 190 
one-way ANOVA with Dunn’s multiple comparisons post-test (Western blots, behavioural 191 
tests) and student’s t-test (immunohistochemistry, electrophysiology) in Prism. 192 
Drugs 193 
Unless otherwise stated, all reagents were obtained from Sigma-Aldrich (St. Louis, Missouri, 194 
USA). Disodium CNQX, picrotoxin, strychnine, DL-TBOA and DL-AP5 were purchased from 195 
Tocris (Bristol, UK). Tetrodotoxin and QX314 chloride were obtained from Alamone Labs Ltd. 196 
(Jerusalem, Israel). 197 
Results 198 
 199 
Nerve injury-induced signs of neuropathic pain and astrocyte activation 200 
In agreement with previous reports, partial sciatic nerve ligation induced reliable signs of 201 
pain (Seltzer et al. 1990) as well as increased staining of GFAP (Coyle 1998; Narita et al. 202 
2006).  From as early as 24 hours post-surgery, nerve injured mice displayed a significant 203 
reduction in the force applied to the injured paw compared to baseline (Figure 1A. left/right 204 
ratio, baseline = 1.08 ± 0.03 vs. Day 1 = 0.44 ± 0.02, P< 0.0001; ANOVA). This change 205 
continued up to and beyond day 7 post-surgery (Day 4 = 0.51 ± 0.04, Day 7 = 0.58 ± 0.07, P< 206 
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0.0001; ANOVA). Similarly, signs of paw lifting, flicking and guarding remained elevated 207 
during the 7 day post-surgical period (Figure 1B. Left vs. right Days 1, 4 and 7 P< 0.0001; 208 
ANOVA). We examined the well established activation of astrocytes following PNL by 209 
examining GFAP staining. As shown in Figure 1C the GFAP immunoreactivity was 210 
significantly elevated after nerve injury with the greatest effect being observed 4 days post-211 
injury. 212 
 213 
Effect of PNL on expression of spinal glutamate transporters 214 
 Following nerve injury, perfusion-fixed mouse spinal cord was sectioned for 215 
immunohistochemical staining of glutamate transporters. Previous reports have indicated 216 
that both glial and neuronal spinal glutamate transporter expression is perturbed by nerve 217 
injury and inflammation (Harris et al. 1996; Sung et al. 2003; Wang et al. 2006; Wang et al. 218 
2008; Xin et al. 2009).  219 
 Modest decreases in astrocytic glutamate transporter expression were observed in 220 
immunohistochemically stained sections of lumbar spinal cord at days 4 and 7 post-injury. 221 
The glial transporters, EAAT1 and EAAT2 (Figure 2A and B, resp.) showed small, persistent 222 
decreases in ipsilateral expression when compared to contralateral dorsal horn. For EAAT1, 223 
the approx. 7% decrease in optical density in the dorsal horn was not significant at either 224 
day 4 or 7 after injury.  However, when both post-injury days were pooled, the decrease was 225 
significant (P < 0.05). For EAAT2, the 9% decreases in optical density for ipsilateral versus 226 
contralateral dorsal horn were significantly reduced on both day 4 and day 7 after injury.  227 
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The small reduction in EAAT2 immunohistochemical staining was then further explored by 228 
Western blot on crudely isolated dorsal horn soluble protein extracts in a separate group of 229 
animals. In these experiments, no significant changes to total EAAT2 levels were found at 230 
either post-injury time point (data not shown). As shown in figure 2D, no trends for changed 231 
expression of EAAT3 were detected immunohistochemically. We should note however, that 232 
the antibody used to detect EAAT3 was from the same species (mouse) as the experimental 233 
animals and is most likely the cause of some non-specific staining, especially in the ventral 234 
horn. However, in concurrent experiments performed without primary antibody (negative 235 
controls), non-specific staining was not observed in the superficial dorsal horn where 236 
analysis was performed (data not shown). Collectively, these data suggest that nerve injury 237 
associated with development of neuropathic pain has only a modest impact on the 238 
expression of glutamate transporters in the spinal dorsal horn.  239 
 240 
Effect of nerve injury on AMPAR synaptic current kinetics. 241 
If the small reduction in immunohistochemical staining for the astrocyte glutamate 242 
transporters, EAAT1 and EAAT2, reflected reduced cell surface expression in the vicinity of 243 
excitatory synapses, then this could lead to reduced extrasynaptic glutamate reuptake. If 244 
this were to occur then kinetics of synaptic currents should be altered. We examined the 245 
kinetics of AMPAR and NMDAR mediated eEPSCs 4 days after injury because maximal 246 
effects on GFAP, as well as decreased expression of EAAT1 and EAAT2, were observed at 247 
that time. 248 
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Example AMPAR- and NMDAR mediated eEPSCs are shown in figures 3A and 3B. 249 
AMPAR and NMDAR eEPSC decay time constants were best fit by single exponentials as 250 
previously described (Feldmeyer et al. 2002; Grosskreutz et al. 2003; Stubblefield and Benke 251 
2010). Fitted time constants did not differ significantly for either the rise (naive; 0.95 ± 0.1 252 
ms, N = 12, injured; 1.0 ± 0.15 ms, N = 10) or decay (naive; 6.15 ± 0.74 ms, N = 23, injured; 253 
6.65 ± 0.95 ms, N = 20) of AMPAR-mediated eEPSCs in naive vs. injured animals, measured 254 
in the presence of DL-AP5 (100 µM), picrotoxin (100 µM) and strychnine (5 µM). Similarly, 255 
NMDAR rise time and decay kinetics, measured in the presence of CNQX (10 µM), picrotoxin 256 
(100 µM) and strychnine (5 µM), were not affected by nerve injury (rise; naive; 6.29 ± 1.09 257 
ms N = 8, injured; 6.63 ± 1.69 ms N = 6, decay; naive; 195.6 ± 24.18, N = 7, injured; 187.8 ± 258 
28.82 N = 7). These findings suggest that impaired glutamate transporter activity might not 259 
contribute greatly to primary afferent synaptic transmission after nerve injury.  260 
 261 
Effect of nerve injury on sensitivity of glutamate transporters to inhibition 262 
Measures of unperturbed decay time constants could be an insensitive measure of 263 
reduced glutamate reuptake in the vicinity of synapses because decay kinetics of both 264 
AMPAR and NMDAR mediated synaptic currents are dominated by channel kinetics rather 265 
than glutamate reuptake (Dingledine et al. 1999). Such measures could also be confounded 266 
by possible changes in subunit composition of AMPARs or NMDARs in pain states (Vikman et 267 
al. 2008) although our data suggest that no such changes occur in mouse dorsal horn, 4 days 268 
after nerve injury. Therefore, to further explore whether enhanced spillover of synaptic 269 
14 
 
glutamate develops after nerve injury, eEPSCs were recorded in the presence of a moderate 270 
concentration of a non-specific glutamate transport inhibitor, DL-threo-β-Benzyloxyaspartic 271 
acid (TBOA) (Shimamoto et al. 1998). By partially blocking glutamate reuptake to induce 272 
detectable spillover from excitatory synapses, any pathologically enhanced spillover of 273 
glutamate produced by nerve injury should be observed as an enhancement of these effects 274 
as previously reported at other CNS synapses (Nie and Weng 2010).  As expected in naive 275 
animals, TBOA (30 and 100 µM) potentiated the duration but not amplitude of AMPAR 276 
eEPSCs in a concentration dependent manner by introducing the appearance of a second, 277 
late phase to the decay of the eEPSC without affecting the early decay phase (Figure 4A,B).  278 
As shown in figure 4B, 100µM TBOA significantly increased the eEPSC late time constant (P = 279 
0.015, from 36.5 ± 8.1 ms to 125.4 ± 20.4 ms, n = 6), as well as the area under the curve (P < 280 
0.05, from 1688 ± 373 pA.ms to 6013 ± 1269 pA.ms, n = 6) in naive animals. Both measures 281 
presumably reflect spillover of glutamate from subsynaptic to extrasynaptic sites and 282 
adjacent synapses. In dorsal horn neurons from untreated animals, transporter inhibition 283 
had no significant effect on the early decay time constant (control = 5.1 ± 0.5 ms, 30 µM = 284 
5.6 ± 1.6 ms, 100 µM = 6.0 ± 1.2 ms), which is presumably dominated by decay kinetics of 285 
channel opening (see also below).    286 
In the presence of TBOA the addition of CNQX (10 µM in the continued presence of 287 
DL-AP5, picrotoxin and strychnine) blocked all slow synaptic currents and nearly abolished 288 
the fast component (n = 3). This suggests that the enhanced slow components of the eEPSC 289 
induced by TBOA are mediated exclusively by AMPARs without any contribution from 290 
mGluRs. mGluR-mediated slow eEPSCs have been reported in dorsal horn in the presence of 291 
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TBOA but only after high frequency stimulation of primary afferent fibres (Galik et al. 2008). 292 
TBOA (100 µM but not 30 µM) also produced a small but significant inhibition of the 293 
amplitude of eEPSCs (14 ± 1.8%), which could be mediated by spillover of glutamate to 294 
presynaptic mGluR (Drew et al. 2008) or KA receptors (Perrais et al. 2010). A 30 µM 295 
concentration of TBOA was therefore selected for subsequent experiments in nerve injured 296 
tissue because it produced only a moderate enhancement of the eEPSC late decay time 297 
constant without affecting amplitude. 298 
 299 
If nerve injury does induce EAAT down-regulation in the vicinity of dorsal horn 300 
primary afferent synapses, glutamate spillover might be enhanced by moderate EAAT 301 
inhibition (30 µM TBOA) to a greater extent in nerve injured than control animals (Figure 302 
3C). As shown in figure 3D, TBOA significantly increased the early decay time constant  in 303 
dorsal horn neurons from nerve injured animals, suggesting that transporters in close 304 
proximity to glutamate release sites might be functionally modified to increase spillover. 305 
Alternatively, nerve injured mice could express more extra-synaptic AMPA receptors in close 306 
proximity to release sites. Nerve injury did not greatly influence distal extra-synaptic 307 
receptor activation as no change to area under the curve, or late decay time constant was 308 
observed following transporter inhibition.  These findings suggest that reduced EAAT activity 309 
in the vicinity of primary afferent synapses, if it occurs after nerve injury, is not due to a 310 
widespread reduction in glutamate uptake capacity but is restricted to proximal 311 
extrasynaptic sites. 312 
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 313 
To ensure that the enhancing effects of TBOA on AMPAR kinetics were not due to 314 
presynaptic actions, miniature EPSCs (mEPSCs) were examined in naive animals. In the 315 
presence of 1µM tetrodotoxin (TTX), no significant changes to mEPSC decay, amplitude or 316 
frequency were observed during glutamate transporter inhibition in naive animals (100 µM 317 
TBOA, N = 4) (Figure 5). This is consistent with the finding that the early decay time constant 318 
of the eEPSC in uninjured mice was unaffected by TBOA and the expectation that mEPSCs, 319 
being sporadic quantal events should produce little spillover to extrasynaptic AMPARs.  320 
 321 
If reduced perisynaptic glutamate transporter activity does indeed explain the 322 
increased early decay time constant of AMPAR-mediated synaptic events via increased 323 
spillover, then it might also be possible to detect increased spillover to NMDA receptors. To 324 
address this, we utilised the use-dependent NMDA receptor blocker (+)-MK-801 to block 325 
subsynaptic NMDARs before enhancing glutamate spillover with TBOA, as reported at this 326 
synapse (Nie and Weng 2009). In this experiment, stable baseline NMDAR-mediated eEPSCs 327 
(in the presence of CNQX) for dorsal horn neurons in whole-cell voltage-clamp (+40mV) 328 
were established by electrically stimulating the dorsal roots at 0.03Hz (Figure 6Ai). Then 329 
active/open NDMARs were blocked during a ten minute superfusion of 50 µM MK-801. At 330 
this time, subsynaptic NMDAR eEPSCs were completely blocked (Figure 6Aii). A ten minute 331 
wash was then performed to remove unbound MK-801 whilst stimulation continued (Figure 332 
6Aii). Following this, 100µM TBOA was superfused onto slices to generate glutamate 333 
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spillover (Figure 6Aiii). As shown in figure 6A, this approach successfully induced glutamate 334 
spillover and activation of extra-synaptic NMDARs. When performed in slices from nerve 335 
injured mice, no change in time to peak was observed (Figure 6B). However a small non-336 
significant trend for increase in peak amplitude and area under the curve were observed. 337 
Collectively however, these findings suggest that no significant increase of spillover to extra-338 
synaptic NMDA receptors takes place following nerve injury. However, this does not rule out 339 
the possibility of increased spillover combined with reduced NMDAR expression. 340 
  341 
Discussion 342 
The present study suggests that nerve injury associated with allodynia and astroglial 343 
activation produces only small changes to expression and function of glutamate 344 
transporters in the vicinity of primary afferent synapses. Our findings therefore argue 345 
against a major role for a contribution of glutamate transporter dysfunction and glutamate 346 
spillover in the development of neuropathic pain. It is well established that peripheral nerve 347 
injury leads to changes in the expression and function of markers of glutamatergic 348 
neurotransmission in the spinal dorsal horn. These changes are also thought to be 349 
responsible, in part, for the development and maintenance of neuropathic pain (Tsuda et al. 350 
2005; Sandkuhler 2007; Scholz and Woolf 2007; Vikman et al. 2008). One of the ways in 351 
which this has been proposed to occur is a generalized down-regulation of glutamate 352 
transporters in the vicinity of synapses and a concomitant increase in the expression and 353 
function of glutamate receptors (Harris et al. 1996; Popratiloff et al. 1998; Garry et al. 2003; 354 
Sung et al. 2003; Yang et al. 2004; Wang et al. 2006; Sung et al. 2007; Tawfik et al. 2008; 355 
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Wang et al. 2008). For example, in rats, PNL induced an approximately 51% and 40% 356 
reduction in EAAT1 (Xin et al. 2009) and EAAT2 (Maeda et al. 2008; Xin et al. 2009), 357 
respectively, expression at day 7. In another model of neuropathic pain, chronic constriction 358 
injury (CCI), these losses are preceded by an increase in EAAT1-3 at day 4 (Sung et al. 2003; 359 
Wang et al. 2006). However, despite an overall increase in total protein at this time, 360 
glutamate reuptake activity was in fact lower than in sham-operated animals (Sung et al. 361 
2003). In contrast to the studies above, we found that nerve injury resulted in modest 362 
decreases in expression over the same 4-7 day period. When we looked at EAAT2 expression 363 
further by Western blot, these reductions were lost. This may be due to transporter 364 
redistribution in astrocytes, exposing changes in epitope availability in 365 
immunohistochemical studies. It is hard to reconcile the differences in EAAT expression 366 
observed between ours and previous studies.  Others have reported increased expression of 367 
all three transporters up to 4 days after chronic constriction injury in rats (Sung et al., 2003)  368 
but decreased expression after 7 days (Sung et al., 2003; Wang et al. 2006). Explanations 369 
could be that of species differences, as our experiments were performed in mice and not 370 
rat, or models used (partial nerve ligation versus chronic constriction injury). For example, in 371 
mice mechanical allodynia and expression changes of nociceptive markers (e.g. NK1) are 372 
typically restricted to the ipsilateral hind paw (Malmberg and Basbaum 1998), whereas in 373 
rat, these changes are bilateral. It has been shown previously partial nerve ligation and 374 
chronic constriction models induce contrasting phenotypes of hot and cold hyperalgesia as 375 
well as mechanical allodynia (Bennett and Xie 1988; Seltzer et al. 1990). These adaptations 376 
were thought to create conditions whereby synaptic glutamate has the potential to both 377 
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persist within the synapse but also to diffuse out of the synapse to bind extra-synaptic 378 
receptors thereby enhancing primary afferent synaptic transmission and plasticity. 379 
 380 
To test whether or not this occurs at functioning synapses, we made use of the 381 
broad-spectrum glutamate transport inhibitor TBOA to drive moderately increased 382 
glutamate spillover in the spinal dorsal horn. By inhibiting all three transporters with 100 383 
μM TBOA, a substantial late phase decay time constant for AMPARs was produced. 384 
Furthermore, the area under the curve of the AMPAR current (current density) increased 385 
from 249% in 30 μM TBOA to 384 % of control in 100 μM TBOA, suggesting a significant role 386 
for EAAT1 and EAAT2 in glutamate reuptake in the dorsal horn. Due to the rapid 387 
desensitization of AMPARs following agonist binding, the facilitation of the synaptic current 388 
under these conditions is likely due to diffusion of synaptically released glutamate to 389 
proximal (early time constant) extra-synaptic AMPARs  and more remote extrasynaptic 390 
receptors and synapses (Beurrier et al. 2009). 391 
 392 
If nerve-injury results in a basal increase in synaptic and perisynaptic glutamate 393 
concentrations, then eEPSCs from nerve-injured mice should display slower decay kinetics 394 
than naïve mice, similar to that observed for TBOA-induced spillover. In the absence of 395 
TBOA, decay time constants did not differ between naive and nerve injured mice suggesting 396 
AMPAR composition in the vicinity of synapses is not greatly altered and spillover, if present, 397 
is modest. Interestingly, nerve injury was associated with an increased early decay time 398 
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constant of AMPARs, suggesting increased peri-synaptic glutamate spillover or, 399 
alternatively, increased perisynaptic AMPAR density.   400 
 401 
This increased early decay time constant after nerve injury in the presence of TBOA 402 
(30 µM) does not appear to be due simply to increased sensitivity to TBOA. Firstly, the late 403 
decay time constant was unaffected after nerve injury in this concentration of TBOA but was 404 
greatly enhanced in control tissue by a higher concentration of TBOA (100 µM). Secondly, 405 
the early decay time constant was completely unaffected by the higher concentration of 406 
TBOA (100 µM) in control spinal cord.  These findings strongly suggest the increased early 407 
decay time constant observed in TBOA reflects either an increased density of extrasynaptic 408 
AMPARs that are silent in the absence of transporter inhibition or, alternatively impaired 409 
transporter (EAAT1 and/or EAAT2) activity in close proximity to synapses that enhances 410 
sensitivity to TBOA.  411 
In a similar study in rats by Nie and Weng (2010), an EAAT2-specific blocker, 412 
dihydrokainate (DHK), significantly increased NMDAR EPSC amplitude, latency, duration and 413 
decay time in naive rats, but failed to elicit any response in nerve injured rats, suggesting 414 
complete loss of EAAT2 function despite expression levels of around 40% compared to 415 
controls. This finding is hard to reconcile with our results. However it should be noted that 416 
these experiments were performed at 8-14 days post-injury in rats, whereas our 417 
electrophysiological recordings were made at day 4 post-injury in mice. 418 
  419 
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The possibility that perisynaptic spillover is increased can also be tested by 420 
examining the effect of TBOA on NMDARs after blockade of active subsynaptic receptors 421 
with MK-801.  In this case there was no significant difference to the degree of extra-synaptic 422 
NMDAR activation at primary afferent synapses from nerve injured animals.  This 423 
experiment therefore failed to confirm the interpretation that the increased early decay 424 
time constants induced by TBOA in nerve injured animals was due to increased perisynaptic 425 
glutamate spillover. There was, however, a non-significant trend for increased peak 426 
amplitude of the extrasynaptic NMDAR-mediated eEPSC which is consistent with a small 427 
increase in spillover. There are other potential explanations for the discrepancy between 428 
the AMPAR and NMDAR-mediated results. It is possible that the increased early decay time 429 
constant of the AMPAR-mediated eEPSC in the presence of TBOA reflects spillover to very 430 
proximal extrasynaptic AMPARs or there may be an increase in extrasynaptic AMPAR 431 
density following nerve injury rather than increased spillover per se. There is evidence for 432 
AMPAR subunit adaptations during inflammatory pain that could be associated with 433 
extrasynaptic insertion of AMPARs (Tao 2010) but whether or not similar adaptations 434 
develop in nerve injury-induced pain is unknown.  It is also possible that spillover to 435 
extrasynaptic NMDARs in the presence of TBOA (100 µM) is mediated more by receptors 436 
more distal to release sites than the AMPARs contributing to the early decay phase 437 
enhanced by nerve injury. If so, measured NMDAR spillover may be similar to the late decay 438 
phase of the AMPAR-mediated eEPSC in the presence of TBOA that is unaffected by nerve 439 
injury. 440 
 441 
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In conclusion, the present study suggests that peripheral nerve injury at a time 442 
associated with neuropathic pain and astrocyte activation does not greatly influence the 443 
expression of astrocytic glutamate transporters in the superficial dorsal horn, nor does it 444 
produce substantial extrasynaptic spillover of glutamate from primary afferent synapses. 445 
However, in the close vicinity of synapses, glutamate transporter function may be prone to 446 
ineffective uptake under extreme circumstances and lead to enhanced receptor activation. 447 
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Figure legends 453 
Figure 1. Effect of nerve injury on the development of neuropathic pain. A) Hind paw 454 
incapacitance test revealing significant weight shift from left (injured) to right hind paw. 455 
Numbers in columns represent number of animals tested. B) PNL produces significant 456 
increase in the rate of spontaneous behaviours indicative of neuropathic pain. C) GFAP 457 
immunoreactivity in a spinal cord section from a nerve injured mouse (inj = 458 
injured/ipsilateral) and histogram revealing significant increase in GFAP densitometry at day 459 
4 post-injury (N = 4 in each group). 460 
 461 
Figure 2. Effect of nerve injury on expression of spinal glutamate transporters. 462 
Immunohistochemistry of glutamate transporters EAAT1 (A), EAAT2 (B) and EAAT3 (C) 463 
following nerve injury reveals significant reduction of EAAT1 and EAAT2 between 4 and 7 464 
days (* = P < 0.05, inj = injured/ipsilateral side, N = 4 in each group). 465 
 466 
Figure 3. Effect of nerve injury on the kinetics of AMPAR and NMDAR-mediated eEPSCs. 467 
Example synaptic current traces from eEPSCs mediated by AMPAR (A) and NMDAR (B) 468 
reveal no significant change to rise or decay kinetics observed after nerve injury. 469 
 470 
Figure 4. Effect of glutamate transporter inhibition on eEPSCs. A) Representative AMPAR 471 
eEPSC showing effect of 30uM TBOA. Thin red lines depict fitted exponentials for early and 472 
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late components of decay. B) Effects of 30 µM and 100 µM TBOA on parameters of AMPAR 473 
eEPSCs in dorsal horn neurons from naive mice expressed as percentage of pre-TBOA 474 
baseline. C) Representative current traces of naive vs. nerve injured mice AMPAR eEPSCs in 475 
the presence of TBOA (30 µM) compared to baseline. D) The effect of 30 µM TBOA on eEPSC 476 
amplitude, decay kinetics and AUC in naive vs. nerve injured mice (percentage increase; * = 477 
P < 0.05, numbers within histograms represent number of cells; N). 478 
 479 
Figure 5. Effect of TBOA on miniature EPSCs. A) Representative recording of mEPSC events 480 
before (CONTROL) and during application of TBOA. Enlarged is a single captured event from 481 
a baseline recording. B) Representative mEPSC traces from averaged events in the presence 482 
of TBOA. The histogram on the right reveals no deviation from baseline for decay, 483 
amplitude, or rate, are observed in the presence of TBOA (N = 4). C) Cumulative probability 484 
plots for current amplitude and rate in the presence of TBOA. 485 
 486 
Figure 6. Effect of nerve injury on glutamate spillover to peri-synaptic NMDARs. A) Example 487 
NMDAR current traces from a from a single dorsal horn neuron at baseline (i), following 488 
washout of MK-801 (ii), and then after superfusion of TBOA (iii). Current traces are overlaid 489 
for comparison in (iv). B) Effect of nerve injury on kinetics of peri-synaptic NMDARs in 490 
presence of TBOA following sub-synaptic NMDAR blockade with MK-801. Numbers within 491 
histogram represent numbers of cells (N). 492 
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